SUBSCRIBE
SUBSCRIBE

Iterion Therapeutics

IN THE PRESS
Lone Star Bio
Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings
February 16, 2021
 · 
4 min read
Business
Apollomics, Inc. and Iterion Therapeutics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Tegavivint in Greater China
February 10, 2021
 · 
5 min read
Drug Development
Iterion Therapeutics Initiates Enrollment of Phase 2a Dose Expansion Study of Tegavivint in Patients with Desmoid Tumors
July 28, 2020
 · 
4 min read
Drug Development
Iterion Therapeutics Initiates Phase I Clinical Study of Tegavivint in Patients with Desmoid Tumors
December 5, 2018
 · 
2 min read
Load More
JOBS